Christoph Jakob Ackermann
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribi K, Maranta A, Bastian S, von Moos R, Jörger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. Eur J Cancer 2024; 200:113600.
05.02.2024First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
05.02.2024Eur J Cancer 2024; 200:113600
Mark Michael, Froesch Patrizia, Gysel Katrin, Rothschild Sacha I, Addeo Alfredo, Ackermann Christoph Jakob, Chiquet Sabrina, Schneider Martina, Ribi Karin, Maranta Angela Fischer, Bastian Sara, von Moos Roger, Jörger Markus, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunol Immunother 2020; 70:563-568.
17.08.2020Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
17.08.2020Cancer Immunol Immunother 2020; 70:563-568
Hasan Ali Omar, Hundsberger Thomas, Diem Stefan, Müller Stefanie, Pop Oltin, Markert Eva, Müller Joachim, Moulin Alexandre, Ring Sandra, Ackermann Christoph Jakob, Berner Fiamma, Flatz Lukas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
08.11.2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
08.11.2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas
The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis
Ackermann C, Gueller U, Jochum W, Schmied B, Warschkow R. The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis. Int J Colorectal Dis 2018
07.06.2018The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis
07.06.2018Int J Colorectal Dis 2018
Ackermann Christoph Jakob, Gueller Ulrich, Jochum Wolfram, Schmied Bruno, Warschkow Rene
Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection
Guebeli N, Warschkow R, Ackermann C, Schmied B, Cerny T, ess s. Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. Swiss Med Wkly 2018; 148:w14583.
29.01.2018Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection
29.01.2018Swiss Med Wkly 2018; 148:w14583
Guebeli Nadia, Warschkow Rene, Ackermann Christoph Jakob, Schmied Bruno, Cerny Thomas, ess silvia
Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection
Gueller U, Warschkow R, Ackermann C, Schmied B, Cerny T, ess s. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. Swiss Med Wkly 2017; 147:w14473.
27.07.2017Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection
27.07.2017Swiss Med Wkly 2017; 147:w14473
Gueller Ulrich, Warschkow Rene, Ackermann Christoph Jakob, Schmied Bruno, Cerny Thomas, ess silvia